AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Aquestive Therapeutics, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00L9HP1R7
4.00▼ 0.13 (-3.15%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
4.13
Day's Range
3.97 – 4.14
52-Week Range
2.93 – 7.18
Volume
1.7M
Avg Volume
2.2M
Share Statistics
Shares Outstanding
Employees
147
Exchange
XNAS
Listed
2018-07-25
Share count as of August 7, 2026

Aquestive Therapeutics, Inc. Common Stock (AQST) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Aquestive Therapeutics, Inc. Common Stock (AQST)
What is Aquestive Therapeutics, Inc. Common Stock's Market Cap?
Aquestive Therapeutics, Inc. Common Stock's Market Cap is $502.0M, based on as-reported figures from SEC (XBRL) filings.
What is Aquestive Therapeutics, Inc. Common Stock's Enterprise Value?
Aquestive Therapeutics, Inc. Common Stock's Enterprise Value is $458.6M, based on as-reported figures from SEC (XBRL) filings.
What is Aquestive Therapeutics, Inc. Common Stock's Price / Sales?
Aquestive Therapeutics, Inc. Common Stock's Price / Sales is 9.3×, based on as-reported figures from SEC (XBRL) filings.
What is Aquestive Therapeutics, Inc. Common Stock's EV / Revenue?
Aquestive Therapeutics, Inc. Common Stock's EV / Revenue is 8.5×, based on as-reported figures from SEC (XBRL) filings.
What is Aquestive Therapeutics, Inc. Common Stock's EV / EBITDA?
Aquestive Therapeutics, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Aquestive Therapeutics, Inc. Common Stock's Revenue (TTM)?
Aquestive Therapeutics, Inc. Common Stock's Revenue (TTM) is $54.1M, based on as-reported figures from SEC (XBRL) filings.
What is Aquestive Therapeutics, Inc. Common Stock's Net Income (TTM)?
Aquestive Therapeutics, Inc. Common Stock's Net Income (TTM) is -$78.2M, based on as-reported figures from SEC (XBRL) filings.
What is Aquestive Therapeutics, Inc. Common Stock's EBITDA?
Aquestive Therapeutics, Inc. Common Stock's EBITDA is -$52.2M, based on as-reported figures from SEC (XBRL) filings.
What is Aquestive Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Aquestive Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is -0.62, based on as-reported figures from SEC (XBRL) filings.
What is Aquestive Therapeutics, Inc. Common Stock's EBITDA Margin?
Aquestive Therapeutics, Inc. Common Stock's EBITDA Margin is -96.6%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AQSTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues
YoY growth+38.1%+65.7%+9.7%-5.4%
Costs and expenses:
Manufacture and supply
Research and development
Selling, general and administrative
Total costs and expenses
% of revenue159.5%129.1%321.6%189.6%
Loss from operations
% of revenue-59.5%-29.1%-221.6%-89.6%
Other income/(expenses):
Loss on extinguishment of debt———
Interest expense
Interest expense related to royalty obligations
Interest expense related to the sale of future revenue
Interest income and other income, net
Net loss before income taxes
Net loss
% of revenue-165.5%-55.8%-244.8%-120.6%
Loss per share attributable to common stockholders:
Basic (in dollars per share)
Diluted (in dollars per share)